Preclinical studies with synthetic peptides in systemic lupus erythematosus
Preclinical studies with synthetic peptides in systemic lupus erythematosus
复制标题
DOI：
10.2741/4030
复制
发表时间：
2012-01-01
影响因子：
3.1
通讯作者：
La Cava, Antonio
中科院分区：
文献类型：
--
作者：
Amarilyo, Gil;Hahn, Bevra;La Cava, Antonio
系统性红斑狼疮（SLE）是一种慢性全身性自身免疫性疾病，可引起多器官损害，并有显著的发病率和死亡率。已经做出各种努力来调节这种疾病中的不平衡免疫应答。通过使用可溶性合成肽作为抗原表位，以重复剂量对免疫系统进行操作，已显示可诱导免疫耐受并减少鼠模型中疾病的临床表现。尽管抗DNA IG肽hCDR 1在人体中的临床试验失败了，但最近用另一种肽p140进行的临床试验结果显示出了希望。本文综述了合成肽在SLE中的临床前和翻译工作。
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that causes multi-organ damage and significant morbidity and mortality. Various efforts have been made to modulate the imbalanced immune responses in this disease. The manipulation of the immune system through the use of soluble synthetic peptides serving as antigenic epitopes, in repeated doses, has been shown to induce immune tolerance and to reduce the clinical manifestations of the disease in murine models. Although clinical trials in humans with the anti-DNA Ig peptide hCDR1 have failed, recent results from a clinical trial with another peptide, p140, have shown promise. This review provides an overview on the preclinical and translational work with synthetic peptides in SLE.